Vancouver December 5th, 2023 – Xtacy Therapeutics Corp. (CSE: XTCY) (Frankfurt: O3X4) (OTCQB: XTCYF) (“the Company) announces expansion of its MDMA research platform to help find solutions to unmet medical needs focused on Perioperative Pain, Social Anxiety Disorder (SAD), Hypoactive Sexual Desire Disorder (HSDD) and Anorexia Nervosa (AN).
The Company is expanding its’ MDMA research platform to pursue financing for clinical trials to include Perioperative Pain, but also Social Anxiety Disorder (SAD), Hypoactive Sexual Desire Disorder (HSDD) and Anorexia Nervosa (AN). There is existing evidence for efficacy in all four indications from studies on MDMA. Leapfrogging some development phases became obvious from the extensive data available from MAPS for both safety and efficacy. This should eliminate the need for additional preclinical, Phase 1 trials – bibliographic data utilisation and allow for an accelerated entry into Phase 2 and Phase 3 trials, saving both time and financial resources to the Company.
The Company has also created a solid IP strategy in place with small Phase 2 trials to gather initial efficacy data and secure patents. The current updated plan is to then open an IND almost immediately based on bibliographic data from MAPS. (https://maps.org/mdma/) The Company has capped trials at $2.5m USD each for the four phase 2 trials. The Australian Psychedelic sector is rapidly growing with a significant influx of Clinical Trials observed in 2023, while MDMA trials are significantly under investigated and Xtacy is glad to already have a signed agreement with Melbourne Australia-based CRO iNGENū.
“We are extremely excited to expand our platform hopeful of transforming mental health treatments. The rationale for MDMA-based therapies has been supported by the extensive new clinical data of MAPS and we are focusing on four high-need, high-TAM indications. This is just the beginning of our change. ” said Meris Kott, CEO.
The Company also announces the resignation of Mr. Mark Ireton as Director. We thank Mark and wish him the best in his future business endeavors.
About Xtacy Therapeutics Corp. :
XTACY is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies and their clinical studies and trials.
For further information visit website:
Or Contact Meris Kott CEO email to [email protected]
Further information about the Company is available on www.SEDARplus.com under the Company’s profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation including statements regarding the future of XTACY Therapeutics and its Phase 2 trials and are based upon the Company’ current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown, risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance, or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, XTACY does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for XTACY to predict all such factors.
When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com including our Management’s Discussion and Analysis. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.